Attorney Docket No.: STK-P01-599

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Keith A. Hruska, et al.

Application No. : 10/650,326 Confirmation No. 6882

Filed : August 28, 2003

For : CONJOINT ADMINISTRATION OF MORPHOGENS

AND ACE INHIBITORS IN TREATMENT OF

CHRONIC RENAL FAILURE

Group Art Unit : 1649

Examiner : Christina M. Borgeest

New York, New York 10036 March 25, 2010

Mail Stop Amendment Hon. Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Supplemental Information Disclosure Statement is filed before the mailing date of a first Office Action after the filing of a Request for Continued Examination under 37 CFR 1.114 (37 CFR 1.97(b)(4)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicants have not submitted a copy of the U.S. patent application. Applicants submit herewith copies of a foreign patent and a non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-1075, under Order No. 003443-0095-101.

Respectfully submitted,

/Ryan D. Murphey/

Karen Mangasarian (Reg. No. 43,772) Attorney for Applicants

Ryan D. Murphey (Reg. No. 61,156) Agent for Applicants

ROPES & GRAY LLP Customer No. 1473 1211 Avenue of the Americas New York, New York 10036

Tel.: (212) 596-9000 Fax: (212) 596-9090